martes, 13 de abril de 2021

A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19 - The Lancet Regional Health – Europe

A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19 - The Lancet Regional Health – Europe

No hay comentarios:

Publicar un comentario